top of page

Marketing department reject new cholesterol reducing drug

The marketing department of a major drug company is refusing to do any work on the company's new cholesterol reducing drug.

Qi ffob, head of marketing, explained that their minimum standard for cholesterol drugs was cholesterol busting. “The public want and need cholesterol busting drugs. Anything less isn’t worth getting out of bed for. It may sound like marketing hype, but trust me, it is.” He went on to say that search engine users often typed in ‘cholesterol reducing’, sometimes typed ‘cholesterol obliterating’ and even ‘cholesterol annihilating’. ‘Busting’, therefore was the absolute minimum acceptable level of efficacy.

A dejected scientist said that although the new drug was effective at reducing cholesterol he understood that public expectations now demanded more than this. He summarised the situation as “Science 0, Idiots 1, again”.

85 views1 comment

Recent Posts

See All

1 Comment

Feb 01

The rejection of a new cholesterol-reducing drug by the marketing department underscores the critical intersection of healthcare and strategic communication. As a digital marketing agency, we understand the delicate balance required in promoting pharmaceutical products. It emphasizes the need for a comprehensive and ethical approach, ensuring that communication aligns with both regulatory standards and patient well-being. Navigating such challenges requires a nuanced strategy, where the expertise of a digital marketing agency can play a pivotal role in crafting responsible and effective messaging for healthcare innovations.

bottom of page